ABSTRACT
This chapter provides investigator-driven registries in post-market research that evaluated the performance of the ABSORB bioresorbable vascular scaffold (BVS) in various clinical settings. The Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe (GHOST-EU) registry is the largest registry involving ten European centers with retrospective data collection. The primary endpoint was target lesion failure (TLF) defined as the combination of cardiac death, target vessel myocardial infarction (MI), and clinically driven ischema-driven target lesion revascularization (TLR). Secondary endpoints included each component of TLF, target vessel failure (TVF), and scaffold thrombosis (ST). The investigator initiated, prospective, single arm, single-center study was conceived to assess the feasibility and performance of the ABSORB BVS for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI). Study endpoints were based on clinical and angiographic data and acute results evaluated with optical coherence tomography (OCT).
